BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) is looking to strengthen its intellectual property base with four UK patent applications related to several novel cancer-specific antigen pairs or "fingerprints" across a range of oncology indications.
The technology being put forward for patent protection will support the development of a pipeline of highly selective cancer therapeutics that use the company's Bi-Cygni approach.
By spotting specific patterns on the surface of a cell, rather than a single cancer identifier, Bi-Cygni treatments are expected to target cancer with superior specificity while eradicating collateral damage.
Chief executive Tiffany Thorn said: “The new patents, if approved, will provide broad protection for our pipeline assets, allowing the development of several generations of cancer-selective Bi-Cygni therapeutics across a wide range of solid tumour and haematological cancers that constitute areas of urgent unmet need.”